Intellia Therapeutics (NTLA) Enterprise Value (2015 - 2026)
Intellia Therapeutics (NTLA) reported Enterprise Value of -$376.0 million for Q1 2026, up 25.36% year-over-year from -$299.9 million in Q1 2025, and up 16.43% quarter-over-quarter from -$449.9 million in Q4 2025.
Intellia Therapeutics (NTLA) Enterprise Value (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of Enterprise Value data on file, last reported at -$376.0 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$376.0 million, up 25.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$376.0 million (up 25.36% YoY), and the FY2025 annual result was -$449.9 million, up 25.21% from the prior year.
- Enterprise Value improved to -$376.0 million in Q1 2026 per NTLA's latest filing, from -$449.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$376.0 million in Q1 2026 and troughed at -$1.2 billion in Q4 2022.
- A 5-year average of -$729.5 million and a median of -$791.3 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value slumped 65.26% in 2022, then jumped 36.34% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$1.2 billion in 2022, then advanced by 23.51% to -$912.2 million in 2023, then surged by 34.06% to -$601.5 million in 2024, then climbed by 25.21% to -$449.9 million in 2025, then grew by 16.43% to -$376.0 million in 2026.
- Business Quant data shows NTLA's Enterprise Value at -$376.0 million in Q1 2026, -$449.9 million in Q4 2025, and -$511.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -375.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -375.99 Mn |
| Dec 31, 2025 | -449.88 Mn |
| Sep 30, 2025 | -511.04 Mn |
| Jun 30, 2025 | -459.65 Mn |
| Mar 31, 2025 | -503.75 Mn |
| Dec 31, 2024 | -601.52 Mn |
| Sep 30, 2024 | -658.11 Mn |
| Jun 30, 2024 | -691.07 Mn |
| Mar 31, 2024 | -791.29 Mn |
| Dec 31, 2023 | -912.22 Mn |
| Sep 30, 2023 | -854.79 Mn |
| Jun 30, 2023 | -908.07 Mn |
| Mar 31, 2023 | -933.54 Mn |
| Dec 31, 2022 | -1.19 Bn |
| Sep 30, 2022 | -828.19 Mn |
| Jun 30, 2022 | -874.28 Mn |
| Mar 31, 2022 | -855.25 Mn |
| Dec 31, 2021 | -750.77 Mn |
| Sep 30, 2021 | -798.27 Mn |
| Jun 30, 2021 | -529.02 Mn |